Infographic Trial Summaries
DR Trials
Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Diabetic Macular Oedema: A Real-World Analysis of 28,658 Patient Eyes
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor (VEGF) vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy (DR): The Protocol W Randomized Clinical Trial
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
The Short-term Effect of a Single Lapse in Anti–Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema (DME) Within Routine Clinical Practice
Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial
Diabetic retinopathy severity and peripheral lesions are associated with nonperfusion on ultrawide field angiography
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (DME)
Baseline factors affecting changes in diabetic retinopathy (DR) severity scale score after intravitreal aflibercept or laser for diabetic macular edema (DME)
Twenty-Four-Month Optical Coherence Tomography Assessment (OCTA) in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy
Preoperative Bevacizumab for Tractional Retinal Detachment in Proliferative Diabetic Retinopathy: A Prospective Randomized Clinical Trial
Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
AMD Trials
‘‘What should I inject next?’’ Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomized, double-masked, phase 3, non-inferiority trials
Efficacy and Safety of Intravitreal Aflibercept Using a Treat-And-Extend Regimen for Neovascular Age-Related Macular Degeneration The ARIES Study: A Randomized Clinical Trial
Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration Early Detection of Neovascular Age-Related Macular Degeneration Study (EDNA)
Efficacy of a treat-and-extend (T&E) regimen with ranibizumab in patients with neovascular age-related macular disease (nAMD): A randomized clinical trial
HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration (nAMD)
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP)
Outcomes of Patients With Exudative Age-Related Macular Degeneration Treated With Antivascular Endothelial Grouth Factor Therapy for Three or More Years: A review of Current Outcomes
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-related Macular Degeneration: 52- and 96-Week Findings From ALTAIR
Ranibizumab Treatment in Treatment-Naive Neovascular Age-related Macular Degeneration: Results From LUMINOUS, A Global Real-World Study
RVO Trials
Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography
Impact of initial visual acuity (VA) on anti-VEGF treatment outcomes in patients with macular edema secondary to retinal vein occlusions (RVO) in routine clinical practice
Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion (RVO)
A 6-month, Subject-Masked, Randomized Controlled Study to Access Efficacy of Dexamethasone as an Adjunct to Bevacizumab Compared With Bevacizumab Alone in the Treatment of Patients With Macular Edema Due to Clinical or Branch Retinal Vein Occlusion
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study
mCNV Trials
Intravitreal Aflibercept Injection in Patients With Myopic Choroidal Neovascularization: The MYRROR Study
PCV Trials
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
ROP Trials
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomized controlled trial
Anti-VEGF Strategy
‘‘What should I inject next?’’ Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD
